Your browser doesn't support javascript.
loading
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.
Mantia, Charlene M; Werner, Lillian; Stwalley, Brian; Ritchings, Corey; Tarhini, Ahmad A; Atkins, Michael B; McDermott, David F; Regan, Meredith M.
Afiliación
  • Mantia CM; Department of Medical Oncology, Dana-Farber Cancer Institute.
  • Werner L; Department of Medicine, Harvard Medical School.
  • Stwalley B; Division of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ritchings C; Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey.
  • Tarhini AA; Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey.
  • Atkins MB; Department of Cutaneous Oncology and Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute.
  • McDermott DF; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida.
  • Regan MM; Department of Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center.
Melanoma Res ; 32(1): 35-44, 2022 02 01.
Article en En | MEDLINE | ID: mdl-34855329

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Melanoma Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Melanoma Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article